FECES: Fecal Transplantation to Eradicate Colonizing Emergent Superbugs
Study Details
Study Description
Brief Summary
Carriage of multi-drug and extensive-drug resistant Gram negative bacteria (MDR-GNB) is associated with an increased risk of infections by these bacteria for the carriers and a high risk of dissemination both in the healthcare setting and the community; the main MDR-GNB reservoir is the fecal microbiota. To prevent both infections and dissemination, effective measures to decolonize subjects carrying MDR-GNB are urgently needed. Animal models, case reports and cohort studies suggest fecal microbiota transplantation (FMT) may be efficient for MDR-GNB decolonization.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
The issue of antibiotic resistance is considered as one of the major Public Health threats of the 21th century by the World Health Organisation (WHO). Given the rapid increase in the dissemination of multi-drug resistant organisms globally, the real implications of spreading drug resistance will be felt the world over, with developing countries and large emerging nations bearing the brunt of this problem. Routine surgeries and minor infections will become life-threatening once again and the hard won victories against infectious diseases of the last fifty years will be jeopardised. Hospital stays and expenses will increase significantly. Drug resistant infections are already on the rise with numbers suggesting that up to 50,000 lives are lost each year to antibiotic-resistant infections in Europe and the US alone. Globally, at least 700,000 die each year of drug resistance in bacterial infections. Estimates have found that antibiotic resistance may kill more than cancer in 2050, with figures reaching 10 million deaths a year globally, if nothing is done.
In this context, one of the most worrying problems is the dramatic increase in infections caused by multi-drug resistant Gram Negative bacteria (MDR-GNB), including extended spectrum β-lactamase and/or carbapenem-resistant Enterobacteriaceae (ESBL-E and CRE) with few effective therapeutic options remaining in the armamentarium of clinicians. There is a striking lack of new antimicrobial agents especially against MDR-GNB while dissemination of these MDR-GNB is accelerating. The rising epidemic of CRE is especially worrying. Southern European countries such as Italy and Greece are already at epidemic levels of CRE infections, which are associated with much higher death rates and are more expensive to treat because of the lack of effective non-toxic antibiotics.
Even if new agents were discovered, the lead in time is considerable as there are no truly new agents expected on the market in the short or medium term. Alternative effective measures to contain resistance and limit the spread of MDR-GNB are therefore urgently needed. The gut microbiota is the main reservoir of MDR-GNB. Patients carrying MDR-GNB are at higher risk of clinical infections with their own bacteria and of dissemination in the community and in the hospital settings. In the last 10 years, the number of MDR-GNB carriers has increased strikingly (for instance, one report found a 10-fold increase in France from 2006-2011 from 0.6% to 6% of subjects in the community; another found a 12% ESBL-E colonization rate in Parisian hospitals upon admission in 2015) and continues to rise. Finding efficient decolonization strategies is urgent to attempt to limit the risk of infection at the individual level and the spread of MDR-GNB at the population level.
Fecal microbiota transplantation (FMT), which has been shown to be highly effective for the treatment of recurrent Clostridium difficile infections (CDI), has also been suggested as a decolonization strategy for patients carrying MDR-GNB: animal models and several clinical case reports suggest that this strategy may be interesting to decolonize MDR-GNB carriers. To date, the question of whether FMT may be efficient to decolonize MDR-GNB carriers in human is not resolved. Because decolonization may also be spontaneous, performing a randomized controlled trial is essential to answer this question.
The hypothesis for this study is that FMT may be efficient to decolonize patients carrying MDR-GNB in their gut microbiota. To determine whether this hypothesis is true, we shall conduct a phase III randomized controlled trial comparing capsule-delivered FMT with a placebo to decolonize subjects carrying either CRE or ESBL-E.
Elimination of carriage should benefit directly the individual patient by preventing infections with these resistant organisms and limiting isolation precautions, which impacts their quality of care, the possibilities of transfer to other healthcare settings (such as rehabilitation centres) and their psychological health. Additionally, the elimination of MDR-GNB carriage should benefit the community by decreasing the risk of inter-individual transmission in particular in the healthcare setting. For this intervention, we will use frozen capsules rather than nasogastric infusion or colonoscopy, as they limit adverse events, facilitate donor screening, allow for outpatient treatment, and are adapted to treat large populations. Thanks to the above-mentioned reasons, capsules are becoming the standard-of-care for FMT. In the context of the major threat that antibiotic resistance in Gram negatives carries, both on an individual and a collective point-of-view; this is a highly important question.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Fecal microbiota Transplant (FMT) Fecal microbiota Transplant (FMT) prepared from the stools of healthy donors diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min) and manufactured in capsules (n=50 capsules corresponding to approximately 50 grams of stool; 25 two days in a row). |
Biological: Fecal Microbiota Transplantation (FMT) capsules
Donated fecal matter will be sequentially diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min). The pellet is resuspended and manually pipetted into size 0 capsules (650 μL), which are closed and then secondarily sealed in size 00 capsules (hypromellose capsules, DR caps from Capsugel®, MA). Each capsule contains 1g ± 0,1g of fecal suspension corresponding to 0.5 to 0.8g of native stool. Capsules will be stored frozen at -80°C for up to 24 months pending use. The stability of biodiversity and viability of the frozen microbiota was regularly verified to ensure the efficacy of the transplantation (personal data).
|
| Placebo Comparator: Placebo of FMT FMT vehicle (solution of saline (NaCl 0.9%)) with 80% glycerol (storage in the same conditions as preparation for FMT experimental group) administered at the same volume and same time point as the experimental group. |
Biological: Placebo capsules
The "placebo" FMT capsules will be performed with the final dilution solution, ie the 80% glycerol solution used as a cryoprotectant. This solution will be double encapsulated like the FMT capsules.
|
Outcome Measures
Primary Outcome Measures
- Determine whether FMT with frozen capsules is effective for decolonization of MDR-GNB. [30 days post-randomization]
Proportion of subjects not carrying MDR-GNB (neither ESBL-E nor CRE) at day 30 (±10 days) after randomization as determined by culture methods
Secondary Outcome Measures
- Prevention of infections [90 days post-randomization]
Occurrence of a clinical infection with ESBL-E or CRE, between randomization and day 90
- Prevention of infections [90 days post-randomization]
Number of days of use of systemic antibiotics between randomization and day 90
- Prevention of infections [up to 2 years post-randomization]
Number of days of isolation precautions during the hospital stay
- Prevention of infections [up to 2 years post-randomization]
Length of stay in hospital
- Safety and tolerability of FMT [2 years post-randomization]
Incidence of Treatment-Emergent Adverse Events
- Microbiology [90 days post-randomization]
Proportion of subjects not carrying MDR-GNB (neither ESBL-E nor CRE) at day 90 after randomization
- Microbiology [Baseline (inclusion), 30 and 90 days post-randomization]
Relative abundance of resistant strains over the total Enterobacteriaceae (expressed as a ratio)
- Microbiology [Baseline (inclusion), 30 and 90 days post-randomization]
Concentration (expressed in colony-forming units per gram of feces) of resistant strains
- Microbiology [Baseline (inclusion), 30 and 90 days post-randomization]
Characteristics of ESBL-E/CPE strains (species identification, resistance mechanisms)
- Microbiology [Baseline (inclusion), 30 and 90 days post-randomization]
16S microbiome analysis, analysis in terms of diversity and operational taxonomic unit (OTU) presence (relative to baseline)
Eligibility Criteria
Criteria
Inclusion Criteria:
Inclusion Criteria for patients:
-
≥ 18 years and < 105 years
-
Inpatients or outpatients with clinical or surveillance isolates with extended spectrum β-lactamase producing Enterobacteriaceae (ESBL-E) and/or carbapenem-resistant Enterobacteriaceae (CRE)
-
Capable of taking oral capsules (25 per day for two days in a row) with no dysphagia or swallowing disorders.
Inclusion Criteria for healthy volunteers donors:
-
Healthy subjects ≥ 18 years and < 50 years
-
Body mass index < 30 kg/m^2
-
Regular bowel movement defined as at least 1 stool every 2 daysand maximum than 3 stools per day
Exclusion Criteria:
Exclusion Criteria for patients:
-
Antibiotic treatment on the day of inclusion except for long term antibiotic prophylaxis (for at least 3 months/year)
-
Patients hospitalized in the intensive care unit
-
Pregnancy or breastfeeding during the study
-
Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control [such as oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (condoms)] to avoid pregnancy for the entire study
-
Patient under legal guardianship
-
Participation in another interventional or minimal risk trial
-
Non-affiliation to a social security scheme (AME excepted)
-
No written informed consent for participation in the study
Exclusion Criteria for healthy volunteers donors:
-
Any history of or current proctologic disease or any acute condition, which in the investigator's judgment could harm the volunteer and/or compromise or limit the evaluation of the protocol or data analysis (for details, please see protocol)
-
Subject under legal protection
-
Participation in any other interventional study
-
Non-affiliation to a social security scheme (AME excepted)
-
No written informed consent for participation in the study
Randomization criteria:
-
Colonized with a carbapenem-resistant Enterobacteriaceae (CRE) at inclusion on stool culture and/or colonized with an extended spectrum β-lactamase producing Enterobacteriaceae (ESBL-E) at inclusion on stool culture
-
Having suffered from an infection with an ESBL-E in the previous 12 months (only for participants no colonized with CRE).
-
Compatible TMF product is available based on CMV/EBV profile
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beaujon Hospital | Clichy | France | ||
| 2 | Henri Mondor Hospital | Créteil | France | ||
| 3 | Raymond Poincaré Hospital | Garche | France | ||
| 4 | Bicêtre Hospital | Le Kremlin-Bicêtre | France | ||
| 5 | Bichat Hospital | Paris | France | ||
| 6 | Bichat Hospital | Paris | France | ||
| 7 | La Pitié Salpêtrière Hospital | Paris | France | ||
| 8 | Lariboisière Hospital | Paris | France | ||
| 9 | Saint Antoine Hospital | Paris | France | ||
| 10 | Saint Louis Hospital | Paris | France | ||
| 11 | Tenon Hospital | Paris | France |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
Investigators
- Principal Investigator: Victoire De Lastours, MD, PhD, Assistance Publique - Hôpitaux de Paris
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- APHP180587
- 2019-004402-10